The Journal of Urology
Volume 181, Issue 5 , Page 2007 , May 2009

Editorial Comment

References 

  1. Attard G, Reid AH, Yap TA, Raynaud F, Dowsett M, Settatree S, et al. Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J Clin Oncol. 2008;26:4563
  2. Scher HI, Beer TM, Higano CS, Danila DC, Montgomery B, Shelkey J, et al. Phase I/II study of MDV3100 in patients (pts) with progressive castration-resistant prostate cancer (CRPC). J Clin Oncol. 2008;26:abstract 5006

PII: S0022-5347(09)00339-5

doi: 10.1016/j.juro.2009.01.140

The Journal of Urology
Volume 181, Issue 5 , Page 2007 , May 2009

Article Tools